HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phase II trial of carboplatin in combination with etoposide in locally advanced large cell carcinoma and adenocarcinoma of the lung.

Abstract
A total of 18 patients with locally advanced (Stage III) adenocarcinoma and large cell undifferentiated carcinoma of the lung, previously untreated, were enrolled in a Phase II trial. Treatment consisted of carboplatin 325 mg/m2, day 1 and etoposide 100 mg/m2 on days 2 and 3. All patients were evaluable for response. Of these, one patient had a partial response (5.5%; confidence interval 0-24%). Toxicity comprised mainly leukopenia and anaemia. Other toxicities were mild. This Phase II study evidenced a poor response rate for these regimes on adenocarcinoma and large cell undifferentiated carcinoma of the lung.
AuthorsR Fuentes, J Dorca, E Canals, A Izquierdo, M Beltrán, P Viladiu
JournalLung cancer (Amsterdam, Netherlands) (Lung Cancer) Vol. 12 Issue 3 Pg. 259-62 (Jun 1995) ISSN: 0169-5002 [Print] Ireland
PMID7655835 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article)
Chemical References
  • Etoposide
  • Carboplatin
Topics
  • Adenocarcinoma (drug therapy)
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Carboplatin (administration & dosage, adverse effects)
  • Carcinoma, Large Cell (drug therapy)
  • Etoposide (administration & dosage, adverse effects)
  • Female
  • Humans
  • Lung Neoplasms (drug therapy)
  • Male
  • Middle Aged

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: